{"product_id":"bcma-nf-kappa-b-reporter-lentivirus-bhv19400259","title":"BCMA\/NFκB Reporter Lentivirus","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc ul{margin:0 0 12px 22px}.bhp-desc li{margin:0 0 6px}\u003c\/style\u003e\n\u003ch2\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eBCMA (B-cell maturation antigen, TNFRSF17) is a tumor necrosis factor receptor superfamily member expressed predominantly on plasma cells and late-stage B cells. Engagement by its ligands BAFF and APRIL promotes plasma cell survival and the maintenance of long-lived antibody-secreting cells, signaling in part through activation of the NF-κB family of transcription factors. Because BCMA is highly and selectively expressed on malignant plasma cells, it has become a leading therapeutic target in multiple myeloma, including for CAR-T and antibody-based approaches. NF-κB reporters linked to BCMA provide a quantitative readout of receptor engagement for studying BCMA signaling and targeted therapeutics.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eProduct Description \u0026amp; Applications\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThe BCMA\/NF-κB Reporter Lentivirus is an all-in-one immunotherapy reporter system for studying BCMA signaling in immune cells. The construct constitutively expresses the human BCMA receptor and couples ligand engagement by BAFF or APRIL to NF-κB-dependent transcription of dual reporters: secreted Gaussia luciferase and a fluorescent protein (GFP or RFP), enabling real-time monitoring by luminometry and fluorescence.\u003c\/p\u003e\n\u003cp\u003eTransducing target cells with the high-titer lentivirus establishes a stable, pathway-specific reporter cell line. Applications include evaluating research-use CAR-T cell activity, studying immune responses in multiple myeloma models, and testing BCMA-targeting therapeutics. Supplied as third-generation, VSV-G-pseudotyped particles purified by PEG precipitation and sucrose gradient centrifugation, the product is effective in difficult-to-transfect primary and thawed cells.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eAbout This Product\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThis 2-vial immunotherapy reporter system consists of a \u003cstrong\u003eVial 1 Receptor Lentivirus\u003c\/strong\u003e encoding human BCMA under a constitutive promoter with antibiotic selection, and a \u003cstrong\u003eVial 2 Reporter Lentivirus\u003c\/strong\u003e encoding tandem NFAT (or NF-κB) response elements driving a dual reporter (GFP, GFP-P2A-GLuc, GLuc, GLuc-P2A-GFP, GLuc-P2A-RFP, RFP, RFP-P2A-GLuc). Sequential transduction and selection generates a dual-stable effector cell line that responds quantitatively to receptor stimulation with a ratiometric fluorescent + bioluminescent readout.\u003c\/p\u003e\n\u003cp\u003eSecreted Gaussia luciferase (where included) accumulates in conditioned media, enabling kinetic sampling without cell lysis. The combined fluorescent and luminescent outputs allow parallel microscopy-based visualization and plate-reader luminometry from the same cell population — providing assay redundancy and flexibility for potency testing formats compliant with regulatory expectations for cell-based functional assays.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"LipExoGen Biotech","offers":[{"title":"GLuc-P2A-GFP \/ Blasticidin \/ 2x10^6","offer_id":53251617194349,"sku":"TRV-0010-6S","price":895.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/Vector-Layout-1024x261_b245fcfb-aad5-4308-afa0-e4ad8837f7dd.jpg?v=1782157779","url":"https:\/\/www.ebiohippo.com\/products\/bcma-nf-kappa-b-reporter-lentivirus-bhv19400259","provider":"BioHippo","version":"1.0","type":"link"}